{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:39:25Z","timestamp":1790419165355,"version":"4.1.0"},"reference-count":38,"publisher":"Consilium Medicum","issue":"3","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>In spite of vaccination was recommended by the World Health Organization, the main strategy of influenza is antiviral drugs treatment, one of which is umifenovir. Aim. The aim of the study is to obtain additional data on safety and therapeutic efficacy of the antiviral drug Arbidol (umifenovir) in patients with a diagnosis of influenza and common cold. Materials and methods. Double-blind, randomized, placebo-controlled clinical study investigating efficacy and safety of Arbidol (umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold (ARBITR) IV phase started in November 2011 and completed in April 2016 on the basis of 15 research centers in various regions of the Russian Federation. A total of 359 patients, aged 18 to 65 years with influenza or acute respiratory tract infection, of no more than 36 hours' duration were enrolled in the study. Patients were randomized into two groups: a group of patients (therapy group) treated by Arbidol (umifenovir) at a dosage of 800 mg\/day (2 capsules) for 5 days (n=181), and a group of patients receiving placebo 4 times a day for 5 days (n=178). The primary outcome measures of the study were the duration of clinical illness among patients with common cold and influenza\/ARVI, the duration and severity of the main symptoms. Number of clinical complications associated with influenza and common cold was assessed as a secondary outcome. Safety was assessed by analyzing number of adverse events that are probably or definitely related to Arbidol, assessing vital signs, examining the physical condition of patients and general clinical laboratory parameters. Results. In the group treated by umifenovir, the number of full recover patients on the 4th day from the disease onset were significantly differed from the number of such cases in the placebo group. The number of cases of complete recovery after 96 hours was 98 patients (54.1%) and 77 (43.3%), p<\/jats:p>","DOI":"10.26442\/00403660.2019.03.000127","type":"journal-article","created":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T15:17:11Z","timestamp":1554045431000},"page":"56-63","source":"Crossref","is-referenced-by-count":28,"title":["Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)"],"prefix":"10.26442","volume":"91","author":[{"given":"N Yu","family":"Pshenichnaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Bulgakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N I","family":"Lvov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"Poromov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E P","family":"Selkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A I","family":"Grekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I V","family":"Shestakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V V","family":"Maleev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A","family":"Leneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Monto A.S. Epidemiology of viral respiratory infections. Am J Med. 2002 Apr 22;112(Suppl 6A):4S-12S.","DOI":"10.1016\/S0002-9343(01)01058-0"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Cox N.J, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51:407-21.","DOI":"10.1146\/annurev.med.51.1.407"},{"key":"ref3","unstructured":"World Health Organization. Influenza (seasonal). 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/ Accessed 12.12.2017."},{"key":"ref4","unstructured":"\u0425\u0430\u0441\u0430\u043d\u043e\u0432\u0430 \u0420.\u0420. \u0414\u0438\u043d\u0430\u043c\u0438\u043a\u0430 \u0441\u043c\u0435\u0440\u0442\u043d\u043e\u0441\u0442\u0438 \u043d\u0430\u0441\u0435\u043b\u0435\u043d\u0438\u044f \u043e\u0442 \u0431\u043e\u043b\u0435\u0437\u043d\u0435\u0439 \u043e\u0440\u0433\u0430\u043d\u043e\u0432 \u0434\u044b\u0445\u0430\u043d\u0438\u044f \u0438 \u0433\u0440\u0438\u043f\u043f\u0430 \u0432 \u0441\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u043e\u0439 \u0420\u043e\u0441\u0441\u0438\u0438. \u041f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u0430\u043d\u0430\u043b\u0438\u0437\u0430 \u0440\u0438\u0441\u043a\u0430. 2017;14(5):72-81."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Maltezou H.C, Tsiodras S. Antiviral agents for influenza: molecular targets, concerns of resistance, and new treatment options. Curr Drug Targets. 2009 Oct;10(10):1041-8.","DOI":"10.2174\/138945009789577972"},{"key":"ref6","unstructured":"World Health Organization. Influenza: BRaVe call to action. 2013. http:\/\/www.who.int\/influenza\/patient_care\/clinical\/call_to_action\/en\/ Accessed 12.12.2017."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30537-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1011506"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/v4123363"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12462"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70295-X"},{"key":"ref13","unstructured":"Guidance for Industry Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). June 2006. https:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/05d-0183-gdl0002-01.pdf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2010.035"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2008.06.002"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0803120"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1086\/318537"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Yacine A, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open forum infectious diseases. Oxford University Press. 2017;4(3):1-10. https:\/\/doi.org\/10. 1093\/ofid\/ofx105","DOI":"10.1093\/ofid\/ofx105"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.3.30445"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1269170"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/092986708784049658"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.021"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.04.006"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617020114"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Leneva I.A, Russell R.J, Boriskin Y.S, Hay A.J. Characteristics of arbidol - resistant mutants of influenza virus: implications for the mechanism of anti - influenza action of arbidol. Antiviral Res. 2009,81(2):132-40. doi: 10.1016\/j. antiviral.2008.10.009","DOI":"10.1016\/j.antiviral.2008.10.009"},{"key":"ref26","unstructured":"\u041b\u044c\u0432\u043e\u0432 \u0414.\u041a., \u0411\u0443\u0440\u0446\u0435\u0432\u0430 \u0415.\u0418., \u0429\u0435\u043b\u043a\u0430\u043d\u043e\u0432 \u041c.\u042e. \u0438 \u0434\u0440. \u041e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u044d\u043f\u0438\u0434\u0435\u043c\u0438\u0438 \u0433\u0440\u0438\u043f\u043f\u0430 \u043d\u0430 \u043e\u0442\u0434\u0435\u043b\u044c\u043d\u044b\u0445 \u0442\u0435\u0440\u0440\u0438\u0442\u043e\u0440\u0438\u044f\u0445 \u0420\u043e\u0441\u0441\u0438\u0438 \u0432 \u044d\u043f\u0438\u0434\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u043c \u0441\u0435\u0437\u043e\u043d\u0435 2012-2013 \u0433\u0433. \u0414\u043e\u043c\u0438\u043d\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0435 \u0448\u0442\u0430\u043c\u043c\u043e\u0432 \u0432\u0438\u0440\u0443\u0441\u0430 \u0433\u0440\u0438\u043f\u043f\u0430 \u0410(\u041d1N1)pdm09 \u0432 \u0441\u0442\u0440\u0430\u043d\u0430\u0445 \u0415\u0432\u0440\u043e\u043f\u044b. \u0412\u043e\u043f\u0440\u043e\u0441\u044b \u0432\u0438\u0440\u0443\u0441\u043e\u043b\u043e\u0433\u0438\u0438. 2014;2:5-10."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011489"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1571306"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.01.001"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Brooks M.J, Sasadeusz J.J, Tannock G.A. Antiviral chemotherapeutic agents against respiratory viruses: wh ere are we now and what\u2019s in the pipeline. Curr Opin Pulmonary Med. 2004;10:197.","DOI":"10.1097\/00063198-200405000-00009"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Megan J. Brooks, Elena I. Burtseva, et al. Antiviral Activity of Arbidol, a Broad-Spectrum Drug for Use Against Respiratory Viruses, Varies According to Test Conditions. J Med Virol. 2012 Jan;84(1):170-81.","DOI":"10.1002\/jmv.22234"},{"key":"ref32","unstructured":"\u041b\u0435\u043d\u0451\u0432\u0430 \u0418.\u0410. \u041c\u0435\u0445\u0430\u043d\u0438\u0437\u043c \u0432\u0438\u0440\u0443\u0441 - \u0441\u043f\u0435\u0446\u0438\u0444\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u0410\u0440\u0431\u0438\u0434\u043e\u043b: \u0414\u0438\u0441\u2026. \u0434.\u0431.\u043d.: 03.00.06 \u041c., 2005:303 \u0441. \u0420\u0413\u0411 \u041e\u0414, 71:06-3\/135."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02077-15"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587188-96"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.12.010"},{"key":"ref37","unstructured":"\u041c\u0430\u043b\u0435\u0435\u0432 \u0412.\u0412., \u0421\u0435\u043b\u044c\u043a\u043e\u0432\u0430 \u0415.\u041f., \u041f\u0440\u043e\u0441\u0442\u044f\u043a\u043e\u0432 \u0418.\u0412., \u041e\u0441\u0438\u043f\u043e\u0432\u0430 E.A. \u0424\u0430\u0440\u043c\u0430\u043a\u043e\u044d\u043f\u0438\u0434\u0435\u043c\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 \u0442\u0435\u0447\u0435\u043d\u0438\u044f \u0433\u0440\u0438\u043f\u043f\u0430 \u0438 \u0434\u0440\u0443\u0433\u0438\u0445 \u041e\u0420\u0412\u0418 \u0432 \u0441\u0435\u0437\u043e\u043d\u0435 2010\/11 \u0433\u0433. \u0418\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u043d\u043d\u044b\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438. 2012;10(3):15-23."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789162-71"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33014\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T22:04:25Z","timestamp":1634162665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.03.000127","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,15]]}}}